A 29-amino acid truncated analog of growth hormone-releasing hormone representing the shortest fully functional biological fragment capable of stimulating pituitary GH secretion.
~12 - 20 minutes
GHRH Receptor
C149H246N44O42S
Administered via subcutaneous injection, typically prior to sleep on an empty stomach.
Multiple randomized controlled trials published in humans.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Sermorelin: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C149H246N44O42S
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Sermorelin was the first GHRH analog approved by the FDA (formerly marketed as Geref) for diagnostic evaluation of pituitary somatotropic function and treatment of pediatric growth hormone deficiency. Because it stimulates endogenous synthesis via the native negative-feedback loop (somatostatin regulation), it avoids tachyphylaxis and excessive supraphysiological GH peaks.
Selectively binds pituitary GHRH receptors on somatotroph cells, activating adenylate cyclase and cAMP second-messenger pathways to stimulate endogenous GH transcription and pulsatile exocytosis.
Peer-reviewed publications, clinical trials, and preclinical research investigating Sermorelin.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Administered via subcutaneous injection, typically prior to sleep on an empty stomach.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
